Published in Expert Rev Hematol on September 01, 2015
Hydroxyurea down-regulates BCL11A, KLF-1 and MYB through miRNA-mediated actions to induce γ-globin expression: implications for new therapeutic approaches of sickle cell disease. Clin Transl Med (2016) 0.77
Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev (2016) 0.75
Low-dose methotrexate in sickle-cell disease: a pilot study with rationale borrowed from rheumatoid arthritis. Exp Hematol Oncol (2017) 0.75
Interventions for chronic kidney disease in people with sickle cell disease. Cochrane Database Syst Rev (2016) 0.75
An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision Medicine. OMICS (2016) 0.75
Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev (2017) 0.75
Interventions for chronic kidney disease in people with sickle cell disease. Cochrane Database Syst Rev (2017) 0.75
Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med (1994) 15.82
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med (1995) 13.59
Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature (1998) 9.30
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA (2003) 8.18
Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ (2008) 7.19
Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood (1998) 6.72
Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science (2008) 6.66
Nomenclature and classification of purinoceptors. Pharmacol Rev (1994) 5.32
Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet (2012) 4.62
A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet (2007) 4.61
DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci U S A (2008) 4.46
Purinoceptors: are there families of P2X and P2Y purinoceptors? Pharmacol Ther (1994) 3.93
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol (2010) 3.78
Endothelium-dependent inhibitory effects of acetylcholine, adenosine triphosphate, thrombin and arachidonic acid in the canine femoral artery. J Pharmacol Exp Ther (1982) 3.33
Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases. J Infect Dis (2005) 3.12
Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. Proc Natl Acad Sci U S A (2007) 3.10
Genetic influences on F cells and other hematologic variables: a twin heritability study. Blood (2000) 2.95
Transcriptional silencing of {gamma}-globin by BCL11A involves long-range interactions and cooperation with SOX6. Genes Dev (2010) 2.93
Evidence for the multicentric origin of the sickle cell hemoglobin gene in Africa. Proc Natl Acad Sci U S A (1984) 2.86
An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science (2013) 2.71
Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood (1999) 2.59
Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood (2003) 2.55
FOG-1 recruits the NuRD repressor complex to mediate transcriptional repression by GATA-1. EMBO J (2005) 2.53
Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet (2010) 2.50
An essential role for free radicals and derived species in signal transduction. FASEB J (1997) 2.50
Control of fetal hemoglobin: new insights emerging from genomics and clinical implications. Hum Mol Genet (2009) 2.44
Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest (1984) 2.43
National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med (2008) 2.43
Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics (2008) 2.42
microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood (2010) 2.34
A functional element necessary for fetal hemoglobin silencing. N Engl J Med (2011) 2.25
MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology (2010) 2.23
Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood (2007) 2.13
Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest (2003) 2.00
Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood (2005) 1.99
Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr (2009) 1.91
MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation. Mol Cancer (2011) 1.89
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatr Blood Cancer (2011) 1.89
Common haplotype dependency of high G gamma-globin gene expression and high Hb F levels in beta-thalassemia and sickle cell anemia patients. Proc Natl Acad Sci U S A (1985) 1.85
Effect of hydroxyurea on ribonucleotide reductase. Biochem Biophys Res Commun (1968) 1.83
Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica (2008) 1.71
A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease. J Natl Med Assoc (2009) 1.70
Repression of c-kit and its downstream substrates by GATA-1 inhibits cell proliferation during erythroid maturation. Mol Cell Biol (2005) 1.67
Bradykinin and ATP stimulate L-arginine uptake and nitric oxide release in vascular endothelial cells. Biochem Biophys Res Commun (1991) 1.64
MAP kinase activation in macrophages. J Leukoc Biol (2001) 1.64
The genomic analysis of erythrocyte microRNA expression in sickle cell diseases. PLoS One (2008) 1.60
Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. Blood (2012) 1.58
Fetal hemoglobin in sickle cell anemia: genetic studies of the Arab-Indian haplotype. Blood Cells Mol Dis (2013) 1.54
A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer (2009) 1.50
Genetic etiologies for phenotypic diversity in sickle cell anemia. ScientificWorldJournal (2009) 1.49
Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype. Blood Cells Mol Dis (2008) 1.43
Genetics of fetal hemoglobin in Tanzanian and British patients with sickle cell anemia. Blood (2010) 1.42
Identification and properties of cyclic nucleotide phosphodiesterases. Mol Cell Endocrinol (1983) 1.41
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal (2012) 1.40
Genetic variation on chromosome 6 influences F cell levels in healthy individuals of African descent and HbF levels in sickle cell patients. PLoS One (2009) 1.39
Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proc Natl Acad Sci U S A (2001) 1.34
Association of thalassaemia intermedia with a beta-globin gene haplotype. Br J Haematol (1987) 1.28
Vasomotor activity of diadenosine triphosphate and diadenosine tetraphosphate in isolated arteries. Am J Physiol (1988) 1.27
Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood (2011) 1.25
Nitric oxide production from hydroxyurea. Free Radic Biol Med (2004) 1.25
Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res (2010) 1.24
Update on fetal hemoglobin gene regulation in hemoglobinopathies. Curr Opin Pediatr (2011) 1.24
Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization. Am J Hematol (2010) 1.23
Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. Proc Natl Acad Sci U S A (2004) 1.22
Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists. Am J Hematol (2005) 1.21
The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol (2013) 1.21
In vivo production of nitric oxide in rats after administration of hydroxyurea. Mol Pharmacol (1997) 1.20
The hydroxyurea-induced small GTP-binding protein SAR modulates gamma-globin gene expression in human erythroid cells. Blood (2005) 1.19
Mortality in sickle cell patients on hydroxyurea therapy. Blood (2004) 1.19
Two independent genetic factors in the beta-globin gene cluster are associated with high G gamma-levels in the HbF of SS patients. Blood (1984) 1.18
Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network. J Natl Med Assoc (2008) 1.18
MAP-kinase signaling pathways in T cells. Curr Opin Immunol (2001) 1.16
MicroRNAs in erythropoiesis. Curr Opin Hematol (2010) 1.15
Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood (2006) 1.12
Hydroxyurea for the treatment of sickle cell disease. Evid Rep Technol Assess (Full Rep) (2008) 1.11
Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica (2010) 1.10
Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea. Mol Pharmacol (1999) 1.09
DNA sequence variation in a negative control region 5' to the beta-globin gene correlates with the phenotypic expression of the beta s mutation. Blood (1992) 1.08
Involvement of p38 kinase in hydroxyurea-induced differentiation of K562 cells. Cell Growth Differ (2001) 1.08
Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. Am J Hematol (2013) 1.06
Sodium butyrate induces transcription from the G alpha(i2) gene promoter through multiple Sp1 sites in the promoter and by activating the MEK-ERK signal transduction pathway. J Biol Chem (2001) 1.05
microRNA expression in erythropoiesis and erythroid disorders. Br J Haematol (2009) 1.05
Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease. Blood (1998) 1.04
Genetic complexity in sickle cell disease. Proc Natl Acad Sci U S A (2008) 1.04
cAMP differentially regulates gamma-globin gene expression in erythroleukemic cells and primary erythroblasts through c-Myb expression. Biochem Biophys Res Commun (2006) 1.02
Hemoglobin E-beta thalassemia: factors affecting phenotype. Indian Pediatr (2005) 1.01
Eukaryotic initiation factor 2α phosphorylation mediates fetal hemoglobin induction through a post-transcriptional mechanism. Blood (2013) 1.00
Negative regulation of gamma-globin gene expression by cyclic AMP-dependent pathway in erythroid cells. Exp Hematol (2004) 1.00
The Xmn1 polymorphic site 5' to the (G)gamma gene and its correlation to the (G)gamma:(A)gamma ratio, age at first blood transfusion and clinical features in beta-thalassemia patients from Western Iran. Mol Biol Rep (2009) 0.98
DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea. Mutat Res (2007) 0.98
EGFR-independent activation of p38 MAPK and EGFR-dependent activation of ERK1/2 are required for ROS-induced renal cell death. Am J Physiol Renal Physiol (2004) 0.98
Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. Arch Dermatol (2001) 0.96
Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia. Am J Hematol (2011) 0.96
Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia. Br J Haematol (2008) 0.96
The nitric oxide producing reactions of hydroxyurea. Curr Med Chem (2003) 0.94
Beta-globin gene haplotypes among cameroonians and review of the global distribution: is there a case for a single sickle mutation origin in Africa? OMICS (2015) 0.94
Association of variants at BCL11A and HBS1L-MYB with hemoglobin F and hospitalization rates among sickle cell patients in Cameroon. PLoS One (2014) 0.93
Limitations of Hb F as a phenotypic modifier in sickle cell disease: study of Kuwaiti Arab patients. Hemoglobin (2011) 0.93
Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. BMC Public Health (2007) 3.68
Supporting the delivery of cost-effective interventions in primary health-care systems in low-income and middle-income countries: an overview of systematic reviews. Lancet (2008) 3.28
Research capacity. Enabling the genomic revolution in Africa. Science (2014) 3.05
Management of neural tube defects in a Sub-Saharan African country: the situation in Yaounde, Cameroon. J Neurol Sci (2008) 1.70
The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study. AIDS (2004) 1.63
Mobile phone text messaging for promoting adherence to anti-tuberculosis treatment: a systematic review. BMC Infect Dis (2013) 1.57
Ascorbic acid deficiency activates cell death and disease resistance responses in Arabidopsis. Plant Physiol (2005) 1.49
Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med (2013) 1.40
Association between fertility and HIV status: what implications for HIV estimates? BMC Public Health (2008) 1.38
Strengthening the expanded programme on immunization in Africa: looking beyond 2015. PLoS Med (2013) 1.32
Frequency and clinical genetics of familial dilated cardiomyopathy in Cape Town: implications for the evaluation of patients with unexplained cardiomyopathy. S Afr Med J (2011) 1.27
Ready to put metadata on the post-2015 development agenda? Linking data publications to responsible innovation and science diplomacy. OMICS (2014) 1.24
The Highly Homologous T-Box Transcription Factors, TBX2 and TBX3, Have Distinct Roles in the Oncogenic Process. Genes Cancer (2010) 1.23
Clinical characteristics and outcomes of familial and idiopathic dilated cardiomyopathy in Cape Town: a comparative study of 120 cases followed up over 14 years. S Afr Med J (2011) 1.20
'Communicate to vaccinate' (COMMVAC). building evidence for improving communication about childhood vaccinations in low- and middle-income countries: protocol for a programme of research. Implement Sci (2011) 1.12
Wealth and sexual behaviour among men in Cameroon. BMC Int Health Hum Rights (2006) 1.05
"Communicate to vaccinate": the development of a taxonomy of communication interventions to improve routine childhood vaccination. BMC Int Health Hum Rights (2013) 1.04
Improved measles surveillance in Cameroon reveals two major dynamic patterns of incidence. Int J Infect Dis (2005) 1.04
Global health: the importance of evidence-based medicine. BMC Med (2013) 1.02
Immunotherapy for tuberculous pericarditis. N Engl J Med (2014) 0.97
Too little, too late: measles epidemic in South Africa. Lancet (2010) 0.96
Fibroblast growth factor receptor-1 is expressed by endothelial progenitor cells. Blood (2002) 0.95
UV-mediated regulation of the anti-senescence factor Tbx2. J Biol Chem (2007) 0.95
Cytochrome P450 pharmacogenetics in African populations: implications for public health. Expert Opin Drug Metab Toxicol (2014) 0.94
Beta-globin gene haplotypes among cameroonians and review of the global distribution: is there a case for a single sickle mutation origin in Africa? OMICS (2015) 0.94
Acceptance of abortion by doctors and medical students in Cameroon. Lancet (2007) 0.90
Factors that affect the uptake of community-based health insurance in low-income and middle-income countries: a systematic protocol. BMJ Open (2014) 0.89
Citation classics in systematic reviews and meta-analyses: who wrote the top 100 most cited articles? PLoS One (2013) 0.89
Understanding interventions for improving routine immunization coverage in children in low- and middle-income countries: a systematic review protocol. Syst Rev (2013) 0.89
Mobile phone text messaging for promoting adherence to anti-tuberculosis treatment: a systematic review protocol. Syst Rev (2013) 0.89
Sickle Cell Disease. N Engl J Med (2017) 0.89
The use of supplementary immunisation activities to improve uptake of current and future vaccines in low-income and middle-income countries: a systematic review protocol. BMJ Open (2014) 0.88
Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis. BMC Infect Dis (2012) 0.87
HIV infection is associated with a lower incidence of constriction in presumed tuberculous pericarditis: a prospective observational study. PLoS One (2008) 0.87
The impact of mass media interventions on tuberculosis awareness, health-seeking behaviour and health service utilisation: a systematic review protocol. BMJ Open (2014) 0.85
Role of splenectomy for immune thrombocytopenic purpura (ITP) in the era of new second-line therapies and in the setting of a high prevalence of HIV-associated ITP. S Afr Med J (2015) 0.85
UCT's contribution to medical genetics in Africa - from the past into the future. S Afr Med J (2012) 0.84
In search of genetic markers for nonsyndromic deafness in Africa: a study in Cameroonians and Black South Africans with the GJB6 and GJA1 candidate genes. OMICS (2014) 0.83
Biomedical research, a tool to address the health issues that affect African populations. Global Health (2013) 0.83
Translating biotechnology to knowledge-based innovation, peace, and development? Deploy a Science Peace Corps--an open letter to world leaders. OMICS (2014) 0.82
Prenatal diagnosis and termination of pregnancy: perspectives of South African parents of children with Down syndrome. J Community Genet (2012) 0.82
Contemporary use of adjunctive corticosteroids in tuberculous pericarditis. Int J Cardiol (2007) 0.81
Initiation of prenatal genetic diagnosis of sickle cell anaemia in Cameroon (sub-Saharan Africa). Prenat Diagn (2011) 0.81
Phosphorylation of histone H3 by protein kinase C signaling plays a critical role in the regulation of the developmentally important TBX2 gene. J Biol Chem (2009) 0.81
Trends in the types and quality of childhood immunisations research output from Africa 1970-2010: mapping the evidence base. BMC Health Serv Res (2014) 0.80
A role for Tbx2 in the regulation of the alpha2(1) collagen gene in human fibroblasts. J Cell Biochem (2007) 0.79
Urethral duplication in a 12-year-old child. Afr J Paediatr Surg (2012) 0.79
Chronic Chlamydia pneumoniae infection and stroke in Cameroon: a case-control study. Stroke (2006) 0.79
Stroke may appear to be rare in Saudi-Arabian and Nigerian children with sickle cell disease, but not in Cameroonian sickle cell patients. Br J Haematol (2006) 0.78
Cytogenetic analysis of 52 Indian patients with de novo myelodysplastic syndromes-a comparative analysis of results with reports from Asia. Ann Hematol (2005) 0.78
Antiviral efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV-infected children and adolescents: a systematic review protocol. Syst Rev (2014) 0.77
Prenatal diagnosis may represent a point of entry of genetic science in sub-Saharan Africa: a survey on the attitudes of medical students and physicians from Cameroon. Prenat Diagn (2006) 0.77
Complex rearrangement of the exon 6 genomic region among Opitz G/BBB Syndrome MID1 alterations. Eur J Med Genet (2013) 0.77
Misoprostol and pregnancy termination. Lancet (2007) 0.75
Report on the 6th African Society of Human Genetics (AfSHG) Meeting, March 12-15, 2009, Yaounde, Cameroon. Am J Trop Med Hyg (2010) 0.75
Monocyte derived dendritic cells have reduced expression of co-stimulatory molecules but are able to stimulate autologous T-cells in patients with MDS. Hematol Oncol Stem Cell Ther (2013) 0.75
Interventions for improving coverage of childhood immunisation in low- and middle-income countries. Cochrane Database Syst Rev (2016) 0.75
Safety of licensed vaccines in HIV-infected persons: a systematic review protocol. Syst Rev (2014) 0.75
Knowledge, attitudes and practices on adolescent vaccination among parents, teachers and adolescents in Africa: a systematic review protocol. Syst Rev (2014) 0.75
The clonogenic potential of selected CD34+ cells from patients with MDS appear preserved when tested ex vivo. Leuk Res (2011) 0.75
Implementation strategies for health systems in low-income countries: an overview of systematic reviews. Cochrane Database Syst Rev (2017) 0.75
Definition of the variables affecting efficacy of immunodepletion ex vivo of peripheral blood progenitor cell grafts by alemtuzumab (Campath in the bag). Biol Blood Marrow Transplant (2013) 0.75
Atrial fibrillation as a consequence of tuberculous pericardial effusion. Int J Cardiol (2012) 0.75
Delivery arrangements for health systems in low-income countries: an overview of systematic reviews. Cochrane Database Syst Rev (2017) 0.75
Governance arrangements for health systems in low-income countries: an overview of systematic reviews. Cochrane Database Syst Rev (2017) 0.75
Cochrane Column. Int J Epidemiol (2016) 0.75